SpotLight Proteomics: uncovering the hidden blood proteome improves diagnostic power of proteomics

• Published in: Scientific reports 2017-02, Vol.7 (1), p.41929-41929, Article 41929
• Main Authors: Lundström, Susanna L., Zhang, Bo, Rutishauser, Dorothea, Aarsland, Dag, Zubarev, Roman A.
• Format: Article
• Language: English
• Subjects: 631/378/1689; 631/45/475; Alzheimer's disease; Antibodies; Blood; Dementia disorders; Etiology; Humanities and Social Sciences; Lewy bodies; Liquid chromatography; Mass spectrometry; Mass spectroscopy; Medicin och hälsovetenskap; multidisciplinary; Neurodegenerative diseases; Nucleotide sequence; Peptides; Proteomics; Science
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/srep41929

The human blood proteome is frequently assessed by protein abundance profiling using a combination of liquid chromatography and tandem mass spectrometry (LC-MS/MS). In traditional sequence database search, many good-quality MS/MS data remain unassigned. Here we uncover the hidden part of the blood proteome via novel SpotLight approach. This method combines de novo MS/MS sequencing of enriched antibodies and co-extracted proteins with subsequent label-free quantification of new and known peptides in both enriched and unfractionated samples. In a pilot study on differentiating early stages of Alzheimer’s disease (AD) from Dementia with Lewy Bodies (DLB), on peptide level the hidden proteome contributed almost as much information to patient stratification as the apparent proteome. Intriguingly, many of the new peptide sequences are attributable to antibody variable regions, and are potentially indicative of disease etiology. When the hidden and apparent proteomes are combined, the accuracy of differentiating AD (n = 97) and DLB (n = 47) increased from ≈85% to ≈95%. The low added burden of SpotLight proteome analysis makes it attractive for use in clinical settings.